A Randomized, 6-week, Open-Label, Study Evaluating The Safety, Tolerability, and Efficacy of Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents

Trial Profile

A Randomized, 6-week, Open-Label, Study Evaluating The Safety, Tolerability, and Efficacy of Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents

Completed
Phase of Trial: Phase III

Latest Information Update: 07 May 2014

At a glance

  • Drugs Lurasidone (Primary)
  • Indications Schizoaffective disorder; Schizophrenia
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms Switch-Core
  • Sponsors Sunovion Pharmaceuticals
  • Most Recent Events

    • 09 Oct 2013 Results presented at the 26th Annual Congress of the European College of Neuropsychopharmacology.
    • 27 Jun 2013 Results presented at the 11th World Congress of Biological Psychiatry.
    • 22 May 2013 Results presented at the 166th Annual Meeting of the American Psychiatric Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top